Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 2/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 4/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097748 | 0.84 | AHR (0.53) | AHRPDK2CMA1PDE3BPDE3A | |
| SCHEMBL986343 | 0.82 | NPC1 (0.55) | AHRPDK2PDE3BPDE3ANPC1 | |
| SCHEMBL8556611 | 0.79 | MAPT (0.58) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL27459742 | 0.73 | TDP2 (0.56) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL1744832 | 0.73 | PDE3B (0.46) | PDE3BPDE3ACYP11B1CYP11B2 | |
| SCHEMBL16907887 | 0.72 | AHR (0.48) | AHRPDK2CMA1PDE3BPDE3A | |
| Oxindole SCHEMBL15636313 | 0.72 | AHR (0.95) | AHRPDK2CMA1PDE3BPDE3A | |
| Oxindole SCHEMBL8866524 | 0.72 | AHR (0.95) | AHRPDK2CMA1PDE3BPDE3A | |
| SCHEMBL3354520 | 0.72 | CYP11B1 (0.41) | PDE3BPDE3ACYP11B1CYP11B2MAOB | |
| SCHEMBL910409 | 0.71 | NPC1 (0.55) | PDE3BPDE3ANPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 982 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201911-A | Compounds and their use as GPR183 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| WO-2024073282-A2 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-04 | — | — | WO | claimed |
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-12 | — | — | US | claimed |
| CN-113004278-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | claimed |
| WO-2023064195-A1 | CGRP ANTAGONISTS FOR TREATING TRIGEMINAL NEURALGIA | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-04-20 | — | — | WO | claimed |
| WO-2023034467-A2 | CGRP ANTAGONISTS FOR TREATING SKIN CONDITIONS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| EP-0462830-B1 | Cyclic ether derivatives | ZENECA LTD (GB) | 1995-10-18 | — | — | EP | claimed |
| US-5364877-A | Antiinflammatory agents, antiallergens | ICI PHARMA (GB) | 1994-11-15 | — | — | US | claimed |
| WO-1994025453-A1 | 4-ARYL-4-HYDROXY-TETRAHYDROPYRANS AND 3-ARYL-3-HYDROXY-TETRAHYDROFURANS AS 5-LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | claimed |
| EP-0623614-A1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-11-09 | — | — | EP | claimed |
| US-5294619-A | N-(nitrogen-containing heterocyclylalkyl-phenyl-piperidines | PFIZER INC. (US) | 1994-03-15 | — | — | US | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| EP-0462831-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | claimed |
| EP-0462830-A2 | Cyclic ether derivatives | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | claimed |
| WO-1990006303-A1 | ARYLPIPERIDINE DERIVATIVES | PFIZER INC. (US) | 1990-06-14 | — | — | WO | claimed |
| EP-0372776-A2 | Arylpiperidine derivatives | PFIZER INC. (US) | 1990-06-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | AHR 998/4885PDK2 3662/4885CMA1 960/4885 |
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | PLK1, HSP90B1, CEP170 | AHR 1922/4885PDK2 1533/4885CMA1 723/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | AHR 1048/4885PDK2 3659/4885CMA1 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.